We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Intervention Study for Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Oregovomab Plus Chemo in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Following Optimal Debulking Surgery

physician hugging cancer patient


AGE: >18 years old
GENDER: Female
CONDITION: Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
TYPE: Drug study

Learn More About This Research Study

For more information, please contact Lauren Patrick at 216-844-8724 or complete the online form below.

Study Purpose

The purpose of this study is to see how safe and effective four doses of the experimental study drug oregovomab is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen paclitaxel and carboplatin.

Who Can Participate

Participants 18 years and older diagnosed with epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot

Study ID